These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37984242)

  • 1. Characteristics and outcomes of surgically staged multiple classifier endometrial cancer.
    Bogani G; Betella I; Multinu F; Casarin J; GhezzI F; Sorbi F; VizziellI G; Petrillo M; Cianci S; Berretta R; PaolinI B; FanfanI F; De Vitis L; Scambia G; Mariani A; Colombo N; Raspagliesi F
    Eur J Surg Oncol; 2024 Jan; 50(1):107269. PubMed ID: 37984242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological characteristics of multiple-classifier endometrial cancers: a cohort study and systematic review.
    De Vitis LA; Schivardi G; Caruso G; Fumagalli C; Vacirca D; Achilarre MT; Aloisi A; Garbi A; Zanagnolo V; Aletti G; Guerini-Rocco E; Mariani A; Maggioni A; Barberis M; Bogani G; Colombo N; Multinu F; Betella I
    Int J Gynecol Cancer; 2024 Feb; 34(2):229-238. PubMed ID: 38135437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.
    León-Castillo A; Gilvazquez E; Nout R; Smit VT; McAlpine JN; McConechy M; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Soslow RA; Ganesan R; Matias-Guiu X; Oliva E; Harrison BT; Church DN; Gilks CB; Bosse T
    J Pathol; 2020 Mar; 250(3):312-322. PubMed ID: 31829447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
    León-Castillo A; de Boer SM; Powell ME; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Singh N; Pollock PM; Bessette P; Fyles A; Haie-Meder C; Smit VTHBM; Edmondson RJ; Putter H; Kitchener HC; Crosbie EJ; de Bruyn M; Nout RA; Horeweg N; Creutzberg CL; Bosse T;
    J Clin Oncol; 2020 Oct; 38(29):3388-3397. PubMed ID: 32749941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
    D'Alessandris N; Travaglino A; Santoro A; Arciuolo D; Scaglione G; Raffone A; Inzani F; Zannoni GF
    Gynecol Oncol; 2021 Nov; 163(2):427-432. PubMed ID: 34446267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
    Leon-Castillo A; Horeweg N; Peters EEM; Rutten T; Ter Haar N; Smit VTHBM; Kroon CD; Boennelycke M; Hogdall E; Hogdall C; Nout RRA; Creutzberg CL; Ortoft G; Bosse T
    Gynecol Oncol; 2022 Mar; 164(3):577-586. PubMed ID: 35078648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
    Bosse T; Nout RA; McAlpine JN; McConechy MK; Britton H; Hussein YR; Gonzalez C; Ganesan R; Steele JC; Harrison BT; Oliva E; Vidal A; Matias-Guiu X; Abu-Rustum NR; Levine DA; Gilks CB; Soslow RA
    Am J Surg Pathol; 2018 May; 42(5):561-568. PubMed ID: 29505428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification.
    Siegenthaler F; Lindemann K; Epstein E; Rau TT; Nastic D; Ghaderi M; Rydberg F; Mueller MD; Carlson J; Imboden S
    Gynecol Oncol; 2022 May; 165(2):230-238. PubMed ID: 35277281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of lymphovascular space invasion according to the molecular subgroups in endometrial cancer.
    Siegenthaler F; Epstein E; Büchi CA; Gmür A; Saner FACM; Rau TT; Carlson JW; Mueller MD; Imboden S
    Int J Gynecol Cancer; 2023 Nov; 33(11):1702-1707. PubMed ID: 37666529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of the TCGA molecular classification in uterine carcinosarcoma.
    Travaglino A; Raffone A; Raimondo D; Arciuolo D; Angelico G; Valente M; Scaglione G; D'alessandris N; Casadio P; Inzani F; Mollo A; Santoro A; Seracchioli R; Franco Zannoni G
    Int J Gynaecol Obstet; 2022 Jul; 158(1):13-20. PubMed ID: 34536971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent POLE hotspot mutations and mismatch repair deficiency/microsatellite instability in endometrial cancer: A challenge in molecular classification.
    Moufarrij S; Gazzo A; Rana S; Selenica P; Abu-Rustum NR; Ellenson LH; Liu YL; Weigelt B; Momeni-Boroujeni A
    Gynecol Oncol; 2024 Dec; 191():1-9. PubMed ID: 39276497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification.
    Thompson EF; Huvila J; Jamieson A; Leung S; Lum A; Offman S; Lytwyn A; Sur ML; Hoang L; Irving J; van der Westhuizen N; Morin C; Bicamumpaka C; Azordegan N; Gougeon F; Ennour-Idrissi K; Senz J; McConechy MK; Aguirre-Hernandez R; Lui V; Kuo C; Bell C; Salisbury T; Lawson J; He E; Wang S; Chiu D; Kean S; Samouëlian V; Salvador S; Gotlieb W; Helpman L; Scott S; Wohlmuth C; Vicus D; Plante M; Talhouk A; Huntsman D; Parra-Herran C; Kinloch M; Grondin K; Gilks CB; McAlpine JN;
    Mod Pathol; 2022 Dec; 35(12):1974-1982. PubMed ID: 36241860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts.
    Fremond S; Andani S; Barkey Wolf J; Dijkstra J; Melsbach S; Jobsen JJ; Brinkhuis M; Roothaan S; Jurgenliemk-Schulz I; Lutgens LCHW; Nout RA; van der Steen-Banasik EM; de Boer SM; Powell ME; Singh N; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Smit VTHBM; Creutzberg CL; Horeweg N; Koelzer VH; Bosse T
    Lancet Digit Health; 2023 Feb; 5(2):e71-e82. PubMed ID: 36496303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk stratification and molecular heterogeneity of endometrial cancer and expression profile of TIM-3: A retrospective cohort study.
    Zhang Y; Yang R; Xu C; Zhang Y; Deng M; Wu D; Tang F; Liu X; Han Y; Zhan Y; Miao J
    Gynecol Oncol; 2023 Mar; 170():210-220. PubMed ID: 36709662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.
    Kim SR; Cloutier BT; Leung S; Cochrane D; Britton H; Pina A; Storness-Bliss C; Farnell D; Huang L; Shum K; Lum A; Senz J; Lee CH; Gilks CB; Hoang L; McAlpine JN
    Gynecol Oncol; 2020 Jul; 158(1):3-11. PubMed ID: 32331700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.
    Similä-Maarala J; Soovares P; Pasanen A; Ahvenainen T; Vahteristo P; Bützow R; Lassus H
    Gynecol Oncol; 2022 Jun; 165(3):577-584. PubMed ID: 35370008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of a one-step genomics-based molecular classifier for endometrial carcinoma in a large Chinese population.
    Kang N; Zhang X; Wang Z; Dai Y; Lu S; Su W; Gai F; Zhu C; Shen D; Wang J
    Pathol Res Pract; 2024 Feb; 254():155152. PubMed ID: 38277742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program.
    RAINBO Research Consortium
    Int J Gynecol Cancer; 2022 Dec; 33(1):109-17. PubMed ID: 36600534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: An emerging target for immunotherapy.
    Zhang Y; Yang R; Xu C; Zhang Y; Deng M; Wu D; Tang F; Liu X; Han Y; Zhan Y; Miao J
    Pathol Res Pract; 2022 Aug; 236():153990. PubMed ID: 35749914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients.
    Wu Q; Zhang N; Xie X
    BMC Cancer; 2022 Nov; 22(1):1157. PubMed ID: 36357827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.